Paper Details

  1. Home
  2. Paper Details

Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience.

Author: LainscakMitja, MoulletChristine, SchönNorbert, TenderaMichal

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Initiation and up-titration of carvedilol in patients with chronic heart failure (CHF) were feasible and safe in daily practice, with efficacy and tolerability comparable to clinical trial results. Carvedilol significantly improved patient well-being, despite suboptimal dosing in many cases. Physicians should strive to prescribe optimal doses of beta-blockers to patients with CHF.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Beta-blockers are well established for treatment of chronic heart failure (CHF). However, the extent of implementation of trial results and guidelines in daily practice remains limited, and information regarding how patients feel is scarce. METHODS: In this prospective observational sur...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ijcard.2007.08.001

データ提供：米国国立医学図書館（NLM）

Carvedilol for Chronic Heart Failure: Bridging the Gap between Clinical Trials and Daily Practice

Chronic heart failure (CHF) is a debilitating condition that requires ongoing medical management. This research examines the use of carvedilol, a beta-blocker medication, in the treatment of CHF in daily practice. The authors conducted a prospective observational survey, analyzing data from over 3700 patients with CHF across ten countries, to assess the efficacy, tolerability, and achieved dosage of carvedilol in real-world settings. Their findings suggest that carvedilol can be effectively and safely implemented in daily practice, demonstrating comparable efficacy and tolerability to clinical trials.

A Bridge Between Science and Practice: Optimizing Carvedilol Treatment

This research highlights the importance of bridging the gap between clinical trials and daily practice. The authors demonstrated that carvedilol, a well-established treatment for CHF, can be effectively implemented in real-world settings, achieving comparable results to clinical trials. Their findings underscore the need for healthcare providers to prioritize the implementation of evidence-based guidelines in their clinical practice, ensuring that patients receive the most effective and appropriate care.

A Heartfelt Journey: Improving Care for Patients with CHF

This research offers a beacon of hope for patients living with CHF. By demonstrating the efficacy and safety of carvedilol in daily practice, the study emphasizes the importance of implementing evidence-based guidelines and prioritizing patient well-being. This research underscores the commitment of healthcare professionals to providing the highest quality care for patients with CHF, enhancing their quality of life and promoting a brighter future.

Dr. Camel's Conclusion

The desert of chronic heart failure can be a challenging journey, but this research offers a roadmap for navigating its complexities effectively. By bridging the gap between clinical trials and daily practice, we can ensure that patients with CHF receive the optimal treatment and support. This commitment to evidence-based practice and patient-centered care holds the potential to improve outcomes and enhance the quality of life for individuals living with CHF.

Date :
  1. Date Completed 2007-11-07
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

17804098

DOI: Digital Object Identifier

10.1016/j.ijcard.2007.08.001

Related Literature

Article Analysis
・Side Effects of carvedilol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.